Abstract: A clock data recovery circuit and a clock data recovery method are provided. The clock data recovery circuit includes a time delay loop (100), a frequency locking loop (200) and a deserializer (300). The time delay loop (100) is configured to delay input data according to a phase of a clock signal to realize phase alignment; the frequency locking loop (200) is connected to the time delay loop (100), and is configured to adjust a frequency of the clock signal according to the delayed input data to make the frequency of the clock signal be consistent with a frequency of the input data; and the deserializer (300) is respectively connected to the time delay loop (100) and the frequency locking loop (200), and is configured to deserialize the input data according to the clock signal.

Abstract: A clock data recovery circuit and a clock data recovery method are provided. The clock data recovery circuit includes a time delay loop (100), a frequency locking loop (200) and a deserializer (300). The time delay loop (100) is configured to delay input data according to a phase of a clock signal to realize phase alignment; the frequency locking loop (200) is connected to the time delay loop (100), and is configured to adjust a frequency of the clock signal according to the delayed input data to make the frequency of the clock signal be consistent with a frequency of the input data; and the deserializer (300) is respectively connected to the time delay loop (100) and the frequency locking loop (200), and is configured to deserialize the input data according to the clock signal.

Abstract: A nitrogenous heterocyclic compound, a preparation method, an intermediate, a composition, and an application. The present invention provides a nitrogenous heterocyclic compound as represented by formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, diastereoisomers thereof, tautomers thereof, solvates thereof, metabolites thereof, or prodrugs thereof. The compound has high inhibitory activity against ErbB2 tyrosine kinase, has good inhibitory activity against human breast cancer cells BT-474, human gastric cancer cells NCI-N87 and the like with high expression of ErbB2, and in addition has relatively weak inhibitory activity against EGFR kinase, that is, the compound is an EGFR/ErbB2 double target inhibitor that attenuates EGFR kinase inhibitory activity or a small-molecule inhibitor having selectivity for an ErbB2 target.

Abstract: A nitrogenous heterocyclic compound, a preparation method, an intermediate, a composition, and an application. The present invention provides a nitrogenous heterocyclic compound as represented by formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, diastereoisomers thereof, tautomers thereof, solvates thereof, metabolites thereof, or prodrugs thereof. The compound has high inhibitory activity against ErbB2 tyrosine kinase, has good inhibitory activity against human breast cancer cells BT-474, human gastric cancer cells NCI-N87 and the like with high expression of ErbB2, and in addition has relatively weak inhibitory activity against EGFR kinase, that is, the compound is an EGFR/ErbB2 double target inhibitor that attenuates EGFR kinase inhibitory activity or a small-molecule inhibitor having selectivity for an ErbB2 target.